EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Effects of emodin in preclinical models of myocardial injury: a systematic review and meta-analysis

Shaoyu Chen, Mengying Zhang, Da Li

Frontiers in Cardiovascular Medicine · 2026-11-12 · 13

DOI: 10.3389/fcvm.2026.1968777 ↗
AbstractBibliografische Angaben

Abstract

Background Emodin, a plant-derived anthraquinone, has shown cardioprotective potential in animal models, but the evidence is dispersed across small preclinical studies. Methods PubMed, CNKI, Embase, and Web of Science were searched from inception to June 18, 2026, for controlled animal studies comparing emodin with vehicle controls in myocardial injury models. Continuous outcomes were pooled using random-effects models and expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Heterogeneity was assessed via I 2 . Leave-one-out analyses assessed robustness, and exploratory subgroup analyses examined heterogeneity. Egger's regression test assessed funnel plot asymmetry for outcomes with at least 10 studies. The protocol was registered with PROSPERO (CRD420261389730). Results Sixteen studies involving 262 animals were included. Emodin significantly reduced creatine kinase (CK, SMD = −11.83, 95% CI: −13.78 to −9.87, I 2 = 0%), creatine kinase-MB isoenzyme (CK-MB, SMD = −7.42, 95% CI: −10.05 to −4.78, I 2 = 83.0%), and lactate dehydrogenase (LDH, SMD = −10.03, 95% CI: −15.52 to −4.55, I 2 = 85.5%). Concomitantly, it improved left ventricular ejection fraction (LVEF, SMD = 5.35,95% CI: 2.76 to 7.94, I 2 = 81.0%) and left ventricular shortening fraction (LVSF, SMD = 3.59, 95% CI: 2.54 to 4.63, I 2 = 0%). Pooled effect directions remained unchanged in leave-one-out analyses. Sparse, correlated subgroups prevented reliable attribution of heterogeneity to individual study characteristics. The LVEF funnel plot was asymmetric. Trim-and-fill imputed two studies, after which the pooled LVEF effect was no longer statistically significant (SMD = 3.50, 95% CI: −0.28 to 7.28; P = 0.07). Conclusions This study suggests that emodin may reduce markers of myocardial injury and improve cardiac function. However, small sample sizes, risk of bias, and heterogeneity among the included studies limit confidence in these findings. Before clinical studies begin, pharmacokinetic research should clarify how exposure to emodin and its metabolites relates to pharmacodynamic effects. Systematic Review Registration : https://www.crd.york.ac.uk/PROSPERO/view/CRD420261389730 , identifier CRD420261389730.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →